Episode

Apple's lawsuit couldn't come at a worse time for OpenAI

Podcast
Equity
Published
Jul 17, 2026
Duration seconds
2082
Processing state
not_requested
Canonical source
https://traffic.megaphone.fm/TCML8548864394.mp3
Audio
https://traffic.megaphone.fm/TCML8548864394.mp3
JSON
/v1/public/podcasts/equity-55848/episodes/apple-s-lawsuit-couldn-t-come-at-a-worse-time-for-openai
Markdown
/podcast/equity-55848/apple-s-lawsuit-couldn-t-come-at-a-worse-time-for-openai.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/equity-55848/episodes/apple-s-lawsuit-couldn-t-come-at-a-worse-time-for-openai/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/equity-55848/apple-s-lawsuit-couldn-t-come-at-a-worse-time-for-openai.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Apple filed a trade secrets lawsuit against OpenAI last Friday, and it's not messing around. The complaint alleges a pattern of misconduct reaching all the way up to OpenAI's chief hardware officer and claims more than 400 former Apple employees now work at the company. OpenAI's response so far has been carefully hedged, and the timing couldn't be worse with the company reportedly eyeing an IPO as early as later this year.    On this episode of TechCrunch's Equity podcast, hosts Kirsten Korosec, Anthony Ha, and Sean O'Kane dig into what the lawsuit could mean for OpenAI's own hardware ambitions and IPO timeline, plus a bigger theme running through the week's news: how much should anyone trust AI companies with their data?    Listen to the full episode to hear more about:  Why Microsoft CEO Satya Nadella is warning enterprises about handing data over to AI labs, and whether open source is really a way out of the “Trojan horse” data-trust problem  How forward-deployed engineers (FDEs) are changing the relationship between AI labs and their enterprise customers  Why General Catalyst just handed David Beckham's health drink startup a $1 billion customer value fund  The scoop on a new $200M drug-discovery startup from an ex-OpenAI researcher  Subscribe to Equity on YouTube, Apple Podcasts, Overcast, Spotify and all the casts. You also can follow Equity on X and Threads, at @EquityPod.  Chapters:  00:00 Intro   00:40 Would you want Sam Altman listening to you?  01:53 Apple sues OpenAI over trade secrets  13:24 Satya Nad…